ISB News

ISB Researchers Show Genetic Risk for Disease Often Reflected in Our Blood

Illustration depicting an individual's genetic risk for disease being "reflected."

Artistic depiction of an individual’s genetic risk for disease being “reflected.” © ISB

Humans do not develop disease overnight. Rather, diseases develop gradually over years — sometimes decades — before symptoms appear, and are due to malfunctioning physiological processes brought about by our genes and environment.

In research just published in the journal Proceedings of the National Academy of Sciences (PNAS), scientists from Institute for Systems Biology (ISB) and partner institutions have shown how an individual’s genetic risk for disease is often reflected in their blood.

“A barrier to this area of research is that you can’t usually access the parts of the body where the disease actually starts to develop,” said Dr. Michael Wainberg, first author of the study. “You’re not exactly going to drill into the skull of someone at risk for depression just to take a brain tissue sample! We used blood as a proxy for what’s going on in the rest of the body.”

Researchers studied blood analyte measurements of nearly 5,000 people and found that those with higher genetic risk for each of several dozen diseases have hundreds of detectable changes in protein levels, metabolite levels, and clinical lab tests. Researchers also found that the changes were frequently present in people with the disease, suggesting the changes represent early warning signs of disease that occur before symptoms appear. Some of these changes directly suggest therapeutic strategies and influences on longevity.

“Monitoring how genetic risk manifests in the blood provides intriguing clues to how we might be able to intervene in avoiding disease before symptoms arise,” said Dr. Nathan Price, co-corresponding author on the paper. “Developing such capabilities is central to the idea of scientific wellness that we have been pursuing at ISB for several years.”

Genetic Risk Study Overview

Study Figure: Conceptual overview

The work is inspired by P4 medicine — an approach pioneered by ISB Co-founder Dr. Lee Hood that is predictive, preventive, personalized, and participatory.

“The holy grail of medicine is identifying and preventing disease long before it manifests. While this remains an aspirational goal, we have made great strides in just the past few years, and this research takes us a step closer,” said Hood, co-corresponding author of the study.

This research builds on other important ISB findings, notably that molecular and physiological information can determine an individual’s biological age, which can serve as a more effective and reliable predictor of overall health than chronological age; that the alpha diversity of an individual’s gut microbiome can be accurately predicted by examining metabolites in the blood; and that combining personal, dense, dynamic data (PD3) clouds with tailored behavioral coaching can optimize wellness and the PD3 clouds can identify early transitions into disease states and facilitate the reversal of some disease states back to wellness.

 

Recent Articles

  • Tackling Lyme Disease with Immunity

    It’s Lyme disease season in many areas of the United States, including the Northeast, the Midwest, and some places on the West Coast. In our latest Research Roundtable event, ISB Associate Professor Dr. Naeha Subramanian discussed the latest Lyme disease research conducted in her lab.

  • Wei Lab

    New Technology Reveals Single Cancer Cells Have Different Appetites for Fatty Acids

    A recently developed method by the Wei Lab at Institute for Systems Biology (ISB) and University of California, Riverside provides new insights into cancer biology by allowing researchers to show how fatty acids are absorbed by single cells. This work was published in the Journal of the American Chemical Society.

  • Glioblastoma tumor slice and corresponding density map

    Looking at Tumors Through a New Lens

    To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.